Delivery Order SPE2DB24D2216-SPE2DB25FGPPB
- Not listed
- The Defense Logistics Agency awarded a $1,872.48 delivery order to AmerisourceBergen Drug Corp for Belbuca 600 microgram films (60 count) under a firm fixed price contract type. The award was issued on September 2, 2025, with an ultimate completion date of September 3, 2025, and represents a non-set-aside competitive award. The product will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $1,644.43 to AmerisourceBergen Drug Corp for Belbuca 300 mcg film (60 count) on August 14, 2025, with an ultimate completion date of August 15, 2025. This firm fixed-price delivery order, which is not set aside, represents a pharmaceutical supply delivery under the company's larger indefinite delivery contract with DLA Troop Support Medical. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for BELBUCA 900 MCG film (60 count) with a ceiling value of $1,791.88 under a firm fixed price contract type. This delivery order, awarded on August 29, 2025, represents a child contract under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The award was made through full and open competition with no set-aside designation. Performance will be completed at the...
- The Defense Logistics Agency awarded a delivery order valued at $1,027.72 to AmerisourceBergen Drug Corp for BELBUCA 150 MCG film (60 units) on September 11, 2025, with an ultimate completion date of September 12, 2025. This competitive award utilized firm fixed pricing and required no set-aside designation. The product will be delivered to AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $2,615.72 firm fixed price delivery order to AmerisourceBergen Drug Corp for Belbuca 900 microgram films (60-count units) on September 9, 2025, with an ultimate completion date of September 10, 2025. This non-competitive, non-set-aside award represents a small-value transaction typical of routine pharmaceutical supply replenishment. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a...
- The Defense Logistics Agency awarded a delivery order valued at $4,370.61 to AmerisourceBergen Drug Corp for the supply of Belbuca 600 MCG film (60 count), a pharmaceutical product used in pain management. This contract is a firm fixed price delivery order with an ultimate completion date of August 12, 2025, and represents a non-set-aside competitive award. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,026.43 to AmerisourceBergen Drug Corp for 60 units of Belbuca 750 mcg film, a buprenorphine-based pain management pharmaceutical. Issued on July 31, 2025, with an ultimate completion date of August 1, 2025, this firm fixed-price delivery order was competitively awarded with no set-aside designation. The contract will be performed at AmerisourceBergen Drug Corp's corporate office location in Conshohocken, Pennsylvania....
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,035.01, is for the supply of Belbuca 150 MCG film, a medication used for pain management. The contract has an ultimate completion date of May 28, 2025 and is not designated as a set-aside. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the...
- The Defense Logistics Agency awarded a delivery order valued at $1,061.52 to AmerisourceBergen Drug Corp for BELBUCA 300 MCG Film (60 count) on July 25, 2025, with completion expected by July 28, 2025. This is a firm fixed price, non-set-aside contract executed as a child order under AmerisourceBergen's broader pharmaceutical supply agreements with DLA. The product is a buccal film formulation used for pain management, reflecting the company's role as a critical pharmaceutical distributor for...
- Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, has been awarded a firm fixed price delivery order contract (SPE2DB22D1103|SPE2DB24FTGM1) by the Defense Logistics Agency (DLA) Troop Support Medical to provide Belbuca 75 MCG film in 60s packages. The delivery order, valued at $1,282.03, has an ultimate completion date of March 14, 2024. Amerisourcebergen Drug Corp serves as the prime contractor for this award, which is not designated as a set-aside contract....
- SPE2DB24D2216Indefinite Delivery Contract
- SPE2DB24D2216-SPE2DB25FGPPBDelivery Order
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on August 18, 2025, for the supply of Belbuca 600 MCG Film in quantities of 60 units. This competitively awarded, firm fixed-price delivery order has a ceiling value of $1,121.71 and an ultimate completion date of August 19, 2025. The award was made by the Defense Logistics Agency (DLA), the Department of Defense's logistics organization responsible for supplying pharmaceuticals and medical materiel to military and veteran healthcare systems. This delivery order is a child contract issued under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. This prime contract vehicle provides comprehensive pharmaceutical support globally, enabling AmerisourceBergen to supply a broad range of medications, vaccines, and medical supplies to support Defense Health Agency operations and other federal healthcare systems. The present award for Belbuca, a transmucosal buprenorphine formulation used in pain management, reflects the company's ongoing role as a critical vendor in the federal medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 8/18/25 |